View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 18, 2022

Sensorion’s sudden sensorineural hearing loss asset fails Phase II test

The asset failed to meet the primary goal of 15 decibels, a substantial improvement in pure tone audiometry in the affected ear from baseline.

Sensorion announced that the Phase II AUDIBLE-S clinical trial of its drug candidate SENS-401 (Arazasetron) to treat sudden sensorineural hearing loss (SSNHL) failed to meet the primary goal.

The asset failed to meet the primary endpoint of 15 decibels (dB), a substantial improvement in pure tone audiometry (PTA) in the affected ear from baseline versus placebo after four weeks of treatment.

That said, a sub-assessment in subjects with hearing threshold greater than or equal to 80dB, indicating severe hearing loss, demonstrated an enhanced response versus placebo at the two drug doses. 

This subset accounted for 30% of the total trial population. 

In the trial, SENS-401 was demonstrated to be safe and well-tolerated. Furthermore, the findings validate the data from the preclinical model of severe noise-induced hearing loss, the company said.

Sensorion will continue to analyse results from the trial, with the secondary endpoints data anticipated in mid-March this year. 

SENS-401 is a small molecule that can be administered orally or through an injection. It is intended to offer protection and preserve the inner ear tissue from damage. The tissue damage could lead to progressive or sequelar hearing impairment. 

The multicentre, double-blind, randomised, placebo-controlled trial enrolled 115 patients.

Subjects with severe or profound SSNHL were enrolled within 96 hours after the development of a sudden and severe hearing loss. 

They were categorised to receive either 29mg and 43.5mg twice the daily oral dose of SENS-401 or a placebo. 

Sensorion CMO Géraldine Honnet said: “We are encouraged by the SENS-401 activity data that showed a continuous improvement from day seven until day 28. 

“We will review the full data as soon as possible and explore in particular the PTA comparisons at day 84 and the other secondary endpoints in the trial to determine the best development path for SENS-401.”

In February 2020, Sensorion obtained approval from the Independent Ethics Committee of Strasbourg in France to include military sites in the Phase II trial of SENS-401 for treating SSNHL.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU